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Summary
 
Chemokine receptors serve as coreceptors for HIV entry into CD4
 
1
 
 cells. Their expression is
thought to determine the tropism of viral strains for different cell types, and also to influence
susceptibility to infection and rates of disease progression. Of the chemokine receptors, CCR5
is the most important for viral transmission, since CCR5 is the principal receptor for primary,
macrophage-tropic viruses, and individuals homozygous for a defective CCR5 allele (
 
D
 
32/
 
D
 
32) are highly resistant to infection with HIV-1. In this study, CCR5-specific mAbs were
generated using transfectants expressing high levels of CCR5. The specificity of these mAbs
was confirmed using a broad panel of chemokine receptor transfectants, and by their non-reac-
tivity with T cells from 
 
D
 
32/
 
D
 
32 individuals. CCR5 showed a distinct pattern of expression,
being abundant on long-term activated, IL-2–stimulated T cells, on a subset of effector/mem-
ory T cells in blood, and on tissue macrophages. A comparison of normal and CCR5 
 
D
 
32 het-
erozygotes revealed markedly reduced expression of CCR5 on T cells from the heterozygotes.
There was considerable individual to individual variability in the expression of CCR5 on
blood T cells, that related to factors other than CCR5 genotype. Low expression of CCR5
correlated with the reduced infectability of T cells with macrophage-tropic HIV-1, in vitro.
Anti-CCR5 mAbs inhibited the infection of PBMC by macrophage-tropic HIV-1 in vitro,
but did not inhibit infection by T cell–tropic virus. Anti-CCR5 mAbs were poor inhibitors of
chemokine binding, indicating that HIV-1 and ligands bind to separate, but overlapping re-
gions of CCR5. These results illustrate many of the important biological features of CCR5,
and demonstrate the feasibility of blocking macrophage-tropic HIV-1 entry into cells with an
anti-CCR5 reagent.
 
C
 
hemokine receptors are 7 transmembrane spanning G
protein–coupled receptors (7TMR)
 
1
 
 that mediate a
variety of functions on leukocytes, particularly cell migra-
tion (1–4). Chemokine signaling through these receptors is
important for the positioning of cells within a tissue, and
possibly also for integrin activation during the multi-step
process of leukocyte extravasation (5, 6). This notion stems
from the ability of pertussis toxin, an inhibitor of G
 
a
 
i ac-
tivity, or anti-chemokine mAbs, to inhibit leukocyte mi-
gration in a variety of inflammatory settings (7–9). Mice def-
icient in certain chemokines or chemokine receptors also
show impaired inflammatory responses (10, 11). Recently,
chemokine receptors have attracted considerable attention
for their role as coreceptors for HIV-1 entry into cells.
Therefore the expression of these receptors regulates not
only leukocyte migration through tissues, but also the in-
fection of cells by different strains of HIV-1.
Chemokine receptors are expressed differentially on leu-
kocyte subsets, which accounts for chemotactic patterns in
vitro, and presumably selective migration of some leukocyte
types in vivo. CCR3, the eotaxin receptor, is expressed
mostly by eosinophils which may account in part for the
 
1
 
Abbreviations used in this paper:
 
 MCP, monocyte chemotactic protein;
MIP, macrophage inflammatory protein; MFI, mean fluorescence inten-
sity; 7TMR, seven trans-membrane spanning receptor.
 
 Some of the mAbs described here will be deposited with the National In-
stitutes of Health AIDS Research and Reference Reagent Program (http:
//www.niaid.nih.gov/reagent).
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selective accumulation of eosinophils at certain inflamma-
tory sites (12–14). The IL-8 receptors also show a selective
expression on neutrophils, and anti–IL-8 therapy in various
animal models inhibits neutrophil migration and associated
tissue injury (15–17). Little is known about chemokine re-
ceptor expression on T cells, although T cells respond to
RANTES, MIP-1
 
a
 
, MIP-1
 
b
 
, and macrophage chemoat-
tractant protein (MCP)-1, MCP-2, and MCP-3 (18–22),
suggesting the involvement of CCR1, CCR2, CCR4, or
CCR5. T cells also respond to the CXC chemokine SDF-1,
which binds CXCR4 (23–25), and IP-10 and Mig, which
bind CXCR3 (26, 27). Determining the expression pattern
of chemokine receptors on T cells at various stages of dif-
ferentiation or activation is important for understanding
T cell migration, particularly subset migration to inflamma-
tory lesions.
The first indication that chemokine receptors might func-
tion as coreceptors for HIV-1 entry came from observa-
tions that RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
 suppressed in-
fection of susceptible cells in vitro by macrophage-tropic
primary HIV-1 isolates (28). The chemokine receptor
CXCR4 was found to support infection and cell fusion of
CD4
 
1
 
 cells by laboratory-adapted, T-tropic HIV-1 strains
(29). CCR5, a RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
 receptor,
was subsequently identified by five separate groups as the
principal coreceptor for primary macrophage-tropic strains
(30–34). CCR3 and CCR2b were also identified as other
coreceptors that supported infection by some strains of
HIV-1 (30, 32), although to date, all known macrophage-
tropic strains use CCR5 as a coreceptor.
The importance of CCR5 for HIV-1 transmission was
underscored by the observation that certain individuals
who had been repeatedly exposed to HIV-1 but remained
uninfected had a defect in CCR5 expression (35–38). CD4
 
1
 
T cells from these individuals were highly resistant in vitro
to the entry of primary macrophage-tropic HIV but were
readily infectable with viruses adapted to grow in trans-
formed T cell lines (35, 39). These non-infectable individ-
uals were found to be homozygous for a defective CCR5
allele that contains an internal 32–base pair deletion (CCR5
 
D
 
32). The truncated protein encoded by this gene is appar-
ently not expressed at the cell surface. CCR5 
 
D
 
32 ho-
mozygous individuals comprise 
 
z
 
1% of the Caucasian
population, and heterozygous individuals comprise 
 
z
 
20%
(35–38). In studies of 
 
.
 
2,700 HIV-1–infected individuals,
no 
 
D
 
32 homozygotes were found, indicating the profound
effect of this genotype on resistance to acquisition of HIV-1
(35–38). Individuals who are heterozygous for the 
 
D
 
32
CCR5 allele have been shown to progress more slowly to
AIDS than wild-type homozygous individuals (36–38), sug-
gesting that CCR5 expression may be altered in these indi-
viduals, and that this affects HIV-1 replication in vivo.
The identity of CCR5 as the principal coreceptor for
primary HIV-1 isolates allows a new understanding of viral
tropism, disease pathogenesis, and disease susceptibility.
CCR5 is also a promising new target for blocking HIV-1
entry into cells. Towards this end, we have developed
mAbs to CCR5. These mAbs were used to identify impor-
tant features on the biology of CCR5. First, CCR5 is ex-
pressed by a distinct subset of T cells, the CD26
 
hi
 
 effector/
memory subset, as well as by macrophages. Second, indi-
viduals heterozygous for the CCR5 
 
D
 
32 allele expressed
markedly reduced levels of CCR5 on the surface of their
T cells. Third, there was considerable variation in expres-
sion of CCR5 from individual to individual within the 
 
1
 
/
 
1
 
population, and levels of expression correlated with suscep-
tibility of cells to infection in vitro. Finally, an anti-CCR5
mAb was able to block, in vitro, macrophage-tropic HIV-1
infection of PBMC, demonstrating the feasibility of mAb
inhibition of this receptor.
 
Materials and Methods
 
Study Subjects.
 
All protocols involving the use of human ma-
terial were reviewed and approved by a human studies commit-
tee. Venous blood was collected from volunteer donors and PBMC
were isolated by ficoll-hypaque density gradient centrifugation.
The PBMC were used to determine CCR5 genotype, CCR5
surface expression, and infectivity of HIV-1.
 
Cells and Cell Lines.
 
PBMCs were isolated as described (12).
To generate CD3 blasts, 2 
 
3
 
 10
 
6
 
 PBMC/ml in RPMI-1640 plus
10% FCS were added to tissue culture plates first coated with the
anti-CD3 antibody TR77. After 4–6 d, blasts were removed to
fresh media and supplemented with recombinant human interleu-
kin 2 (rhIL-2; Hoffmann-LaRoche, Nutley, NJ) at 100 U/ml. Other
cell lines used included transfectants of the L1.2 murine pre B cell
lymphoma, expressing high levels of CCR3 (13), CXCR1 and
CXCR2 (40), CXCR3, CXCR4, CCR2b, CCR4, CCR5 (41),
and CCR1 (42) (kindly provided by Dr. Eugene Butcher, Stan-
ford University, Stanford, CA). For most receptors, L1.2 transfec-
tants were also generated with the octapeptide Flag epitope,
which allowed detection (in most cases) with anti-Flag mAb.
Transfectants were maintained in RPMI-1640 supplemented
with 10% bovine serum and 800 
 
m
 
g/ml G418, except for certain
transfectants of CCR5 (see below). The different transfectants were
monitored for expression of the relevant receptors, using mAbs
specific for CCR3, CCR2, CXCR1, CXCR2, CXCR3, CXCR4
(14, 18), and in some cases anti-Flag mAb M2 (Kodak Scientific
Imaging Systems, Rochester, NY). For CCR5, expression was also
monitored by ligand binding and Scatchard analysis. Other cell lines,
such as the T cell and myelomonocytic cell lines, were obtained
from the American Type Culture Collection (Rockville, MD).
 
In Vitro Infection of HIV-1.
 
Subjects were chosen based upon
CCR5 genotype. Two homozygous 
 
1
 
/
 
1
 
 individuals (pts 1 and
2), four 
 
1
 
/
 
D
 
32 heterozygotes (patients 3, 4, 5, and 6), and two
 
D
 
32 homozygotes (patients 7 and 8, previously called EU3 and
EU2, respectively (34, 35, 39), were chosen for in vitro infection
studies. Isolated PBMC were stimulated with phytohemagglutinin
(PHA-P, 5 
 
m
 
g/ml) or anti-CD3 (14) and carried in culture me-
dium (RPMI 1640 supplemented with 10% heat-inactivated fetal
bovine serum). IL-2 was added at 100 U/ml after 3 d. On the days
indicated, CD4
 
1
 
 T cells were enriched by removal of CD8
 
1
 
 cells
using anti-CD8 immunomagnetic beads (Dynal, Great Neck,
NY). Isolates of HIV-1 were added to 2 
 
3
 
 10
 
5
 
 activated CD4
 
1
 
lymphocytes at an inoculum of 600 TCID50 as previously deter-
mined by end-point dilution on random donor activated PBMC
(multiplicity of infection [MOI] 
 
5 
 
0.003). Viruses included the
macrophage-tropic isolate JR-CSF (43) and the T cell line-
adapted variant of SF162 called R3H (44). Infected cultures were
carried for 11 d with feeding and p24 sampling on days 4, 7, and 
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11. HIV p24 production was determined by commercial ELISA
(Abbott Laboratories, Abbott Park, IL). In some experiments, anti-
CCR5 antibody or recombinant chemokines RANTES, MIP-1
 
a
 
,
and MIP-1
 
b
 
 were added to the wells at the time of infection.
 
Construction of CCR5 Stable Transfectants.
 
CCR5 cDNA was
obtained by PCR using a 5
 
9
 
-oligonucleotide primer and 3
 
9
 
-oli-
gonucleotide primer that contained flanking XhoI and XbaI sites,
respectively. For one set of transfectants, the 5
 
9
 
-primer also con-
tained a Flag epitope (Asp.Tyr.Lys.Asp.Asp.Asp.Asp.Lys). The PCR
fragment was subcloned into the XhoI-XbaI sites of pCDNA3
(Invitrogen) and this construct was designated CCR5/pCDNA3.
Another expression vector, CCR5/pMRB101, was also construc-
ted in which the CCR5 cDNA was subcloned into the HindIII–
XbaI sites of pMRB101 (kindly provided by Martin Robinson).
PCR fragments were sequenced to ascertain the sequence fidel-
ity. In both of these expression vectors, the inserted gene was
driven by a CMV promoter. The DNA was stably transfected
into a murine pre-B lymphoma cell line (L1.2) as described (13,
41), except for the CCR5/pMRB101 construct, where mycophe-
nolic acid-selective medium was used to select for transfectants.
The cell surface expression of CCR5 was monitored by ligand
binding and Scatchard analysis. For mAb production, the cell line
transfected with CCR5/pMRB101, treated with 5 mM butyric
acid for 16–18 h, was used exclusively for immunizing mice.
 
PCR Analysis of Genomic DNA.
 
Genomic DNA was isolated
from PBMC of selected blood donors using Trizol reagent ac-
cording to the manufacturer’s instruction (GIBCO BRL). Up-
stream and downstream oligonucleotide primers for amplifying
the CCR5 gene correspond to the second extracellular region of
CCR5, and their sequences were as follows: 5
 
9
 
-primer: GAA-
GTTCCTCATTACACCTGCAGCTCTC; 3
 
9
 
-Primer: CTT-
CTTCTCATTTCGACACCGAAGCAGAG. Using this set of
primers, the wild-type CCR5 allele will give rise to a PCR frag-
ment of 174 bp, whereas the deleted allele will be 142 bp. For
each PCR reaction (100 
 
m
 
l volume), 1 
 
m
 
g genomic DNA was
first denatured at 95
 
8
 
C for 5 min, and amplified by 5 cycles of
PCR (94
 
8
 
C, 45 s; 55
 
8
 
C, 45 s; 72
 
8
 
C, 45 s) followed by an addi-
tional 35 cycles (94
 
8
 
C, 45 s; 62
 
8
 
C, 45 s; 72
 
8
 
C, 30 s). The reaction
products (25 
 
m
 
l) were run on a 4% Nusieve GTG agrose gel and
DNA bands stained by ethidium bromide.
 
mAbs, Immunofluorescent Staining, and FACS
 
Ò
 
 
 
Analysis.
 
mAbs re-
active with CCR5 were generated by immunizing mice with
L1.2 cells expressing high levels of transfected CCR5-Flag (41).
10 female C57BL6 mice were immunized with 10
 
7
 
 cells, intra-
peritoneally, six times at 2-wk intervals, and 8 fusions were per-
formed in an attempt to identify a CCR5-specific mAb. 3 d after
an i.v. injection of CCR5 L1.2 cells, the spleen was removed and
cells were fused with the SP2/0 cell line as described (45). Gener-
ally 5,000–8,000 hybridomas were screened per fusion. In only one
of the eight fusions were anti-CCR5 mAbs detected. The mAbs
generated were 3A9 (IgG2a), 5C7 (IgG2a), 2F9 (IgG2a), 3D8
(IgG2a), 2C4 (IgG2a), 5D7 (IgG2a), 5H11 (IgG2b), and 1G4
(IgG2a). These mAbs were screened for reactivity on both
CCR5-Flag as well as unflagged CCR5 L1.2 transfectants, and
numerous other flagged and unflagged receptor transfectants. The
anti-CXCR4 12G5 (46) was kindly provided by Jim Hoxie (Uni-
versity of Pennsylvania). PE-conjugated mAbs to CD4, CD8,
CD14, CD20, CD25, CD26, CD69, CD45RO, and CD45RA
were obtained from Becton Dickinson (San Jose, CA). Similar
mAbs, as well as anti-CD95 PE, anti-CD3 Cy-Chrome, and anti-
CD4 Cy-Chrome were supplied by PharMingen (La Jolla, CA).
To assess reactivity of mAbs against transfected cells or leuko-
cytes, indirect immunofluorescence and flow cytometry were used.
Cells were washed once with PBS, and resuspended in 100 
 
m
 
l
PBS containing 2% human serum and 0.1% sodium azide (stain-
ing
 
 
 
buffer), 5 
 
m
 
g/ml purified antibody, 5 
 
m
 
g/ml IgG
 
2a
 
 isotype
matched control mAb (Sigma Chemical Co., St. Louis, MO), or
50 
 
m
 
l hybridoma culture supernatant. After 20 min at 4
 
8
 
C, cells
were washed twice with staining
 
 
 
buffer and resuspended in 50 
 
m
 
l
FITC-conjugated affinity-purified F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA). After
incubating for 20 min at 4
 
8
 
C, cells were washed twice in staining
buffer and analyzed on the FACScan
 
Ò
 
 to determine the level of
surface expression. Propidium iodide was used to exclude dead
cells.
 
Tissues, Immunohistochemistry.
 
Normal human mediastinal lymph
node was obtained from the National Disease Research Interchange
(NDRI, Philadelphia, PA). Immunohistochemical analysis for
CCR5 was performed on frozen tissue samples using techniques
previously described (47). The anti-CCR5 mAb 2F9 (10 
 
m
 
g/ml
in 0.3% Triton X-100, 0.2% Tween 20, 1% FCS, 5% human AB
serum, 0.1% sodium azide) were applied to tissue sections that
were incubated overnight at 4
 
8
 
C. An isotype-matched irrelevant
mAb (UPC10; Sigma) was used at the same concentration as a
negative control on step sections of mediastinal node. Subse-
quently, biotinylated goat anti–mouse IgG and avidin-biotin-alka-
line phosphatase complexes (Biogenex, San Ramon, CA) were
added in sequence. Fast Red (Biogenex), containing levamisol to
block endogenous alkaline phosphatase activity, was used as the
chromogen and Mayers hematoxylin as the counterstain.
 
Results
 
Expression of CCR5 on Human Leukocytes.
 
Eight mAbs
were generated to CCR5, by immunizing C57BL6 mice with
the murine pre–B cell lymphoma line, L1.2, expressing trans-
fected human CCR5. These transfectants expressed 
 
z
 
240,000
MIP-1
 
a
 
 binding sites per cell, as determined by ligand
binding and Scatchard analysis (not shown). These mAbs,
termed 3A9, 2F9, 5C7, 3D8, 2C4, 5D7, 5H11, and 1G4,
reacted with L1.2 cells expressing CCR5, but not with
L1.2 cells expressing the other chemokine receptors CCR1,
CCR2, CCR3, CXCR1, CXCR2, CXCR3, CXCR4, or
wild type L1.2 cells. The FACScan
 
Ò
 
 profile of the various
transfectants, stained with a representative mAb, 3A9, is
shown in Fig. 1 
 
A
 
.
The reactivity of mAb 3A9 against certain human leuko-
cyte types, and leukocyte cell lines, is outlined in Table 1.
3A9 stained a subset of blood lymphocytes, usually be-
tween 10–20% of cells. 3A9 was unreactive with most
CD14
 
1
 
 monocytes, and was also unreactive with B cells
(CD20
 
1
 
 cells), eosinophils (CCR3
 
1
 
), and neutrophils (Ta-
ble 1). Of all the T cell lines we examined, the PM1 line
was the only line that expressed appreciable levels CCR5,
which correlates with the infectability of this line with
macrophage-tropic HIV-1 (48, 49).
Since lymph nodes are a major reservoir of HIV-1 dur-
ing the course of infection (50), immunohistochemical stain-
ing of mediastinal lymph node was also performed. Cells
immunoreactive for CCR5 were identified in the paracor-
tex (70%), medulla (20%), and subcapsular sinus (10%). The
paracortex contained small clusters of 10–20 intensely im-
munoreactive cells that were morphologically consistent1684 CCR5 Expression and HIV Infection
with T cell blasts (Fig. 1 B). The lymph node medulla con-
tained scattered, individual immunoreactive cells that re-
sembled macrophages (Fig. 1 C). The subcapsular sinus con-
tained a mixture of the two cell types.
CCR5 Is Expressed on a Distinct Subset of Effector/Memory
T Cells. For most blood donors, the most distinctive ex-
pression of CCR5 was by CD31 T cells (Table 1). The
proportion of CD31 cells stained was usually 10–20% of
cells, with a heterogeneous staining intensity. A two-color
immunofluorescence analysis of lymphocytes showed that a
subset of both CD41 cells and CD81 cells expressed CCR5
(Fig. 2). These CCR51 T cells expressed high levels of
CD45RO, and low levels of CD45RA, a phenotype that is
consistent with previous activation (51). An analysis using
other markers indicative of previous cellular activation,
such as CD26, showed that CCR5 was expressed on all
CD26hi T cells, as well as some CD26intermediate cells. How-
ever CCR51 cells expressed only low levels of markers for
acute activation, such as CD25 (IL-2R), and CD69 (not
shown). CCR51 T cells were also CD95(Fas)1, and were
mostly L-selectin2, a phenotype consistent with previous
activation. A three-color immunofluorescence analysis us-
ing a third color anti-CD4 CyChrome revealed that CD41
cells coexpressed CCR5 and the above lymphocyte mark-
ers in essentially the same pattern as that shown for ungated
lymphocytes (not shown).
Lymphocytes from 1/D32 and D32/D32 Individuals Ex-
press Markedly Reduced Levels of CCR5. The CCR5 mu-
tant allele occurs at a frequency of 0.092 in the Caucasian
population (35, 36). Individuals homozygous or heterozy-
gous for the CCR5 mutant allele were identified by
screening individuals at low and high risk for HIV-1 infec-
tion, using PCR. Fig. 3 A shows the PCR pattern for the
three types of individuals: wild-type homozygous (1/1),
heterozygous (1/D32), and homozygous for the deletion
(D32/D32). A representative immunofluorescent staining
of blood lymphocytes from each type of individual is shown in
Fig. 3 B. An interesting finding was the very weak expression
of CCR5 on 1/D32 individuals. As expected, lympho-
cytes from D32/D32 individuals were CCR5 negative.
Table 1. Reactivity of Anti-CCR5 mAb 3A9 with Various 
Leukocytes and Leukocyte Cell Lines
Cell type % positive MFI
T cells (CD31) 14 (n 5 30) 40
B cells (CD201) 22
Neutrophils 22
Eosinophils 22
Monocytes 5 10
Sup-T1 (T cell line) 22
PM1 (T cell line) 20 13
Hut-78 (T cell line) 22
Jurkat (T cell line) 22
Molt4 clone 8 (T cell line) 22
CEM (T cell line) 22
Ramos (B cell line) 22
THP-1 (myelomonocytic) 22
KGla (myelomonocytic) 22
U937 (myelomonocytic) 22
HL-60 (myelomonocytic) 22
HMC-I (mast cell line) 30 25
Cells were stained with mAb 3A9, and analyzed on the FACSÒ. Mean
fluorescence intensity was derived using CellQuest software. For T cells
and monocytes, MFI was calculated for the positively stained subset
only. The value for the negative control staining was always ,8.
Figure 1. Identification of
CCR5-specific mAbs. (A) mAb
3A9 staining of various L1.2
transfectants. Stable L1.2 trans-
fectants expressing either CCR1,
CCR2b, CCR3, CCR4, CCR5,
CXCR1 (IL-8 RA), CXCR2
(IL-8RB), CXCR3, and CXCR4
(fusin/Lestr) were stained with
anti-CCR5 mAb 3A9. Negative
control staining for all the L1.2
transfectants (not shown) resem-
bled the staining shown for 3A9
on CCR1 L1.2 cells. (B) Lym-
phoblast as well as small lympho-
cyte staining within the paracor-
tical region of mediastinal lymph
node. (C) macrophage staining
within the medullary region of a
mediastinal lymph node. Pho-
tomicrographs (B) 3400; (C)
3500.1685 Wu et al.
T cells from individuals of each genotype were stimu-
lated with anti-CD3, and were then incubated with IL-2
for varying periods of time. T cells derived from 1/1 in-
dividuals stimulated in this fashion for 3 wk showed a
marked upregulation of CCR5, while similarly treated cells
from D32/D32 individuals were still negative for CCR5
expression (Fig. 3 C). T cells derived from 1/D32 individ-
uals showed a staining intensity almost 1 log less than that
of 1/1 T cells, indicative of a 5–10-fold reduced expres-
sion and consistent with the markedly reduced levels of
CCR5 observed on resting T cells from 1/D32 individu-
als. Peak expression of CCR5 on stimulated T cells from
1/1 and 1/D32 individuals required 3 wk of in vitro cul-
ture, at which time the majority of cells expressed CCR5.
In these cultures, CCR5 expression was upregulated stead-
ily from day 4, and the addition of IL-2 was obligatory for
peak CCR5 expression. IL-2 has been reported to be an
important stimulant for CC chemokine receptor expression
(52), which we confirmed here at the protein level for
CCR5.
Heterogeneity of CCR5 Expression by 1/1 and 1/D32 In-
dividuals. The results of staining of lymphocytes of 36 1/1
individuals, 11 1/D32 individuals, and 4 D32/D32 indi-
viduals, to determine the range and heterogeneity of
CCR5 expression within each genotype, is depicted in Fig.
4. This analysis established that the pattern of CCR5 ex-
pression for most individuals showed a good correlation
with CCR5 genotype, although a few 1/1 individuals
showed low levels of CCR5, and T cells from a minority
of 1/D32 individuals expressed slightly elevated levels of
CCR5. Another important finding from this analysis was
the considerable heterogeneity of CCR5 expression with
the 1/1 and 1/D32 groups. This heterogeneity could be
seen by assessing the percentage of cells positive for CCR5,
as well as the mean fluorescence intensity of the CCR51
subset (Fig. 4). Lymphocytes from all four D32/D32 indi-
viduals were CCR52, and mean fluorescence intensity
(MFI) for this category was not determined.
Infectability of PBMC from 1/1, 1/D32, and D32/D32
Individuals with Macrophage-tropic HIV-1 Correlates with CCR5
Expression. PBMC from various blood donors, expressing
different levels of CCR5, were examined for their infect-
ability with a macrophage-tropic strain of HIV-1, JR-CSF
(43), or a T-tropic strain, R3H (44). Infectability with
HIV-1 and surface expression of CCR5 were performed
simultaneously on activated CD41 PBMC from eight sub-
jects encompassing the three major known CCR5 geno-
types. The two CCR5 wild-type homozygotes (pts 1 and
2) had the greatest number of CD41 cells with surface ex-
pression of CCR5 (9.8–12.5%, Fig. 5 A). Similar to what is
shown in Fig. 4, there was variability in the percentage of
CD41 cells expressing CCR5 among the heterozygotes.
Expression ranged from levels observed in wild-type ho-
mozygotes (9%) to that observed in CCR5 D32 homozy-
Figure 2. CCR5 expression on
various populations of blood lym-
phocytes. A two-color staining
protocol was used to assess for ex-
pression of CCR5 (x-axis in all
plots) and the T cell subset markers
CD4 and CD8, the naive/memory
markers CD45RO and CD45RA,
the activation markers CD26 and
CD25, as well as L-selectin, CD95
(Fas) and CD56. The subset
marker staining (y-axis) is indi-
cated for each plot. Quadrants
were set according to the staining
of control mAbs. The staining was
representative of eight donors ana-
lyzed.1686 CCR5 Expression and HIV Infection
gotes (,2%, which is within the background level of de-
tection). As expected, the surface expression of CXCR4
did not vary according to CCR5 genotype (Fig. 5 B).
There was a close association between the number of CD41
cells with surface expression of CCR5 and infectability of
those cells by the macrophage-tropic isolate, JR-CSF (Fig.
5 A). Infection by the T-tropic isolate R3H was not af-
fected by the expression of CCR5 nor did it correlate
closely with the percentage of cells that expressed CXCR4,
although there was variation in their ability to be infected
by T-tropic viral isolate for reasons that remain unclear.
These results indicate that the number of CD41 cells that
express CCR5 upon activation is a major determinant of
the in vitro susceptibility to macrophage-tropic virus infec-
tion.
Anti-CCR5 mAb Inhibits Macrophage-tropic HIV-1 Infection
of Primary T Cells. The ability of anti-CCR5 mAbs to in-
hibit HIV-1 infection of PBMC was assessed. A prelimi-
nary analysis showed that mAb 3A9 was the most effective
inhibitor of macrophage-tropic HIV-1 infection of PBMC.
As shown in Fig. 6 A, a high concentration of mAb 3A9,
when added at the time of virus inoculation, was able to neu-
tralize .95% of infection by the macrophage-tropic isolate
JR-CSF. This was similar to the amount of inhibition
observed when 200 ng each of recombinant RANTES,
MIP-1a, and MIP-1b were added to the culture (Fig. 6 A).
Neither the anti-CCR5 mAb nor the recombinant chemo-
kines had any inhibitory effect upon infection with the
T-tropic strain, R3H (Fig. 6 B). To determine the sensitiv-
ity of JR-CSF to neutralization by mAb 3A9, the antibody
was added to PBMC at the time of virus inoculation in se-
rial fivefold dilution (Fig 6 C). mAb 3A9 was able to in-
hibit JR-CSF infection on PHA-activated PBMC with
ID50 and ID90 values of 0.5–2.3 mg/ml and 15.3–17.2
mg/ml, respectively. mAb 3A9 (and to a lesser extent the
other anti-CCR5 mAbs) also inhibited viral entry in the
single round replication of an env-complemented recombi-
nant HIV-1 virus (not shown).
The anti-CCR5 mAbs were also tested for their ability
to inhibit the binding of 125I-MIP-1a to CCR5 transfec-
tants, and also for their ability to block chemotaxis of CD3
blasts to MIP-1b. mAb 3A9, when used at 100 mg/ml, in-
hibited binding of 125I-MIP-1a to CCR5 transfectants by
only z10%, compared with that obtained with 100 nM of
cold chemokine, and similar results were obtained with the
other anti-CCR5 mAbs. These results suggest that the an-
Figure 3. Expression of CCR5 on T cells from normal (1/1), het-
erozygous (1/D32), and D32 homozygous (D32/D32) individuals. (A)
Identification of 1/1, 1/D32, and D32/D32 individuals by PCR. Ge-
nomic DNA was isolated from PBMC of selected blood donors. PCR re-
actions were carried out using a set of 59- and 39- primers as described in
Materials and Methods, and the reaction products were run on a 4%
Nusieve GTG agarose gel and DNA bands stained by ethidium bromide.
Under these conditions, a 174-bp band was detected for a 1/1 individ-
ual (donor 5), a 142-bp band for D32 homozygous individuals (donors 1
and 2), and both 172- and 142-bp bands for heterozygous (1/D32) indi-
viduals (donors 3 and 4). Lane M shows the molecular weight markers.
(B) Assessment of CCR5 expression on blood lymphocytes from 1/1,
1/D32, and D32/D32 individuals. Lymphocytes from the three types of
individuals were stained with the anti-CCR5 mAb 3A9, and analyzed on
the FACSÒ. Dot plots show fluorescence intensity (y-axis) and forward
scatter (cell size, x-axis). The horizontal line in each plot indicates the
point above which cells were considered positive, based on isotype-
matched control staining. This level of staining in all three plots resem-
bled the staining of 3A9 shown for the D32/D32 individual. The staining
profiles shown were representative of over 35 analyzed for 1/1 individ-
uals, 11 for 1/D32 individuals, and 4 for D32/D32 individuals, although
variability was observed (see below). (C) Staining of anti-CD3–activated,
rhIL-2–stimulated T cells from 1/1, 1/D32 and D32/D32 individuals.
PBMC were activated with anti-CD3 mAb, and maintained in rhIL-2 for
21 d. Cell size (forward light scatter) is shown on the x-axis, and staining
with mAb 3A9 on the y-axis.
Figure 4. Heterogeneity of CCR5 expression. Blood lymphocytes
from 36 1/1 individuals, 11 1/D32 individuals, and 4 D32/D32 indi-
viduals were assessed for percentage CCR5 positive (3A9 staining) cells
(left), and MFI of the positive subset (right). Each point represents the
value obtained for a single individual. Staining was performed using mAb
3A9, and FACSÒ analysis. To calculate MFI, the positively stained subset
was gated, according to control staining, and MFI was calculated using
CellQuest software.1687 Wu et al.
tigenic epitope of human CCR5, recognized by this panel
of mAbs, is not central for ligand binding. We were also
unable to demonstrate mAb inhibition of T cell chemotaxis
to MIP-1b with mAb 3A9 (not shown).
Discussion
The importance of CCR5 as a cofactor for macrophage-
tropic HIV-1 entry into cells led us to develop reagents that
might block this entry. We also used these mAbs to exam-
ine the expression of CCR5 on human leukocytes, and in
particular to document individual to individual differences
in the levels of CCR5 expression on blood T cells.
On T cells, CCR5 was found to be expressed by a dis-
tinct subset of CD45RO1 memory T cells, most of which
expressed high levels of CD26, and CD95 (Fas). This ex-
pression pattern explains the findings of some previous
studies. CD45RO1 as well as CD261 T cells are selectively
lost during the first stages of HIV-1 infection (53, 54), and
loss of T cell memory is a hallmark of HIV-1 infection (55).
Moreover, activated and memory T cells carry most of the
viral burden in HIV-1 infected individuals (53). CCR5 was
also found to be expressed by activated T cells in vitro, and
by lymphoblasts in lymph nodes. Replication of HIV-1 oc-
curs predominantly in the activated population of CD41
T cells (56), and the efficiency of HIV-1 infection is en-
Figure 5. CCR5 surface expression correlates with macrophage-tropic
HIV infectability. PBMC from 8 subjects were tested for CCR5 geno-
type by PCR. Genotypes are represented by (1) for a wild-type allele and
(2) for a D32 allele. PBMC were stimulated with anti-CD3 antibody and
carried for 16 d in the presence of rhIL-2. CD81 cells were depleted us-
ing immunomagnetic beads. Expression of CCR5 or CXCR4 on the sur-
face of CD41 cells was determined by dual staining with anti-CD4 anti-
body and mAb 3A9 (CCR5) or 12G5 (CXCR4), respectively, on a
FacsCaliberÒ (Becton Dickinson). Enriched CD41 cells were inoculated
at 2 3 105 cells per well with 600 TCID50 of JR-CSF (a) or R3H (b) and
p24 production was measured on days 4, 7, and 11. Based on the growth
rates of the two isolates in vitro, day 4 and day 11 p24 results for JR-CSF
and R3H, respectively, are shown (dark bars) in comparison to percentage
of cells expressing specific coreceptors (stippled bars).
Figure 6. Inhibition of macrophage-tropic HIV-1 infection of PBMC
by anti-CCR5 mAb. 7-d PHA-activated CD41 cells from two CCR5
wild-type homozygotes (LW4 and LW5) were inoculated with 600
TCID of JR-CSF (a) or R3H (b) alone (n) or in the presence of 100 mg/ml
of CCR5 mAb 3A9 (l) or 200 ng each of recombinant RANTES, MIP-1a,
and MIP-1b (s). HIV-1 p24 production was measured over the course
of 9 d. To determine the sensitivity of JR-CSF to inhibition by 3A9, the
amount of viral inhibition was calculated when serial fivefold dilutions of
mAb 3A9 were added to the PBMC at the time of virus inoculation (c).
50% inhibitory doses (ID50) on LW4 (n) and LW5 (u) PBMC were 0.5
and 2.3 mg/ml. 90% inhibitory doses (ID90) were 17.2 and 15.3 mg/ml.1688 CCR5 Expression and HIV Infection
hanced in the setting of an antigen-specific immune activa-
tion (57, 58). CCR5 was found to be absent from most
transformed T cell lines, and these lines are known to ex-
press high levels of CXCR4, the T-tropic coreceptor (46,
59). The expression pattern of CCR5 also correlated with
the chemotactic properties of T cells. RANTES is a che-
moattractant for a subset of effector/memory (CD45RO1)
T cells (21). We have found that MIP-1a and MIP-1b also
selectively attract CD45RO1 T cells (18), although other
groups have reported conflicting results on this topic (re-
viewed in reference 60). In migration assays, CD26hi T cells
are the most responsive to CC chemokines (18, 19), are the
most efficient at transendothelial migration, and are abun-
dant within certain inflammatory lesions (61). These cells
most likely represent a highly migratory, post-activation,
effector type T cell.
A central question is why do primary HIV-1 isolates use
CCR5 over other receptors, and what are the reasons for the
emergence of T-tropic virus late in the disease course. An
important feature of CCR5 is its high expression on effec-
tor/memory T cells. The loss of these cells, more than any
other cell type, is what leads to the deterioration of immune
responses. This may allow changes that would not normally
happen in the face of a healthy immune response. It is pos-
sible that the gp120 of T-tropic HIV-1 is more easily neu-
tralized by antibodies (62), or is more effectively combated by
cytotoxic T cells, and this protection is lost in the later
stages of disease following the loss of effector/memory T cells.
Nevertheless other factors may also contribute to receptor
useage during the course of infection. Chemokine receptor
expression may change dramatically, and upregulation or
downregulation of individual receptors may influence the
types or numbers of cellular targets for infection. An analy-
sis of individuals at various stages of HIV-1 infection may
shed light on this question.
There was individual to individual variation in the ex-
pression of CCR5 on blood lymphocytes. Variation in the
extent of MIP-1b binding to CCR5 on activated CD41
T cells from different individuals has also been reported
(63). The importance of CCR5 as an HIV-1 coreceptor
suggests that variability in the expression of CCR5 within
the CCR5 1/1 and 1/D32 genotypes may have impor-
tant consequences for HIV-1 transmission or AIDS patho-
genesis. For instance, individuals with numerous CCR5hi
cells at mucosal surfaces may be at greater risk of contract-
ing HIV-1. Also, greater numbers of CCR5hi CD41 cells
in blood or tissues may lead to more rapid viral spreading,
and quicker progression to AIDS. The apparent advantage
that CCR5 1/D32 individuals have with respect to disease
progression would support this proposition. The examina-
tion of a relatively small number of individuals indicated
that levels of CCR5 expression correlate with macrophage-
tropic HIV-1 infectability, in vitro. Further experiments will
be required to establish whether the same principle holds in
vivo. The factors that influence CCR5 expression in vivo
are currently unknown, but may relate to the degree of im-
mune challenge or activation. To a certain extent, expres-
sion of CCR5 in blood relates simply to the percentage of
effector/memory (CD26hi) T cells, but may also relate to
other factors such as exposure to inflammatory cytokines. A
variety of experiments using in vitro activation of T cells
supports the notion that the efficiency of HIV-1 infection
is enhanced in the setting of immune activation (57). In
sub-Saharan Africa, the increased risk of acquiring HIV-1
infection on exposure to the virus, and the more rapid dis-
ease progression compared to that seen in the western
world, is thought to result from a heightened level of anti-
genic activation in these individuals (64).
CCR5-deficient individuals are generally resistant to in-
fection with HIV-1 (35–38), which has spurred efforts to
develop inhibitors of HIV-1 binding to CCR5. A major aim
of this study was to develop a mAb that could block
macrophage-tropic HIV-1 infection of human T cells. An-
tibodies directed against the HIV-1 exterior glycoprotein,
gp120, exhibit only very weak neutralizing activity against
primary macrophage-tropic HIV-1 isolates and have been
shown to enhance the entry of some primary isolates in
vitro (65, 66). Chemokines themselves will inhibit HIV-1
binding, but they have potent agonist activity, and in
some cases may enhance HIV-1 replication (67). Truncated
chemokines can act as receptor antagonists, exemplified by
a truncated form of RANTES (amino acids 9–68) that in-
hibits macrophage-tropic HIV-1 infection of CCR5 bear-
ing cells (68), although only at very high concentrations.
The mAbs described here were able to inhibit macrophage-
tropic HIV-1 infection of PBMC by .95%. These mAbs
inhibited viral entry, yet interestingly were only weak in-
hibitors of MIP-1a binding. This is consistent with other
studies showing that chemokines and HIV-1 interact with
CCR5 at separate though potentially overlapping sites (69,
70). CCR5-specific mAbs may be of use for establishing
that a CCR5 antagonist might contain viral infection and
reduce viral load. However additional studies will be nec-
essary to ascertain the ability of an antibody to inhibit mul-
tiple independent strains of macrophage-tropic HIV-1, and
to be sure such an antibody does not accelerate develop-
ment of the more cytopathic T-tropic strains of HIV-1.
CCR5 antagonists would presumably be of most benefit
during the early stages of infection, before the evolution of
T-tropic, CXCR4 binding HIV-1 strains.
In conclusion, anti-CCR5 mAbs enabled the blocking
of macrophage-tropic HIV-1 infection in vitro, and also
provided data on the expression of this coreceptor on hu-
man leukocytes. These reagents should provide further in-
teresting insights, particularly into the biology of CCR5
and the pathogenesis of AIDS.
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